Resident
Instituto Português de Oncologia de Lisboa, Portugal
Miguel Oliveira Santos is a medical professional specializing in oncology and is currently in his third year of Medical Oncology Residency at the Instituto Português de Oncologia de Lisboa Francisco Gentil, one of Portugal's leading cancer treatment centers. His journey in medicine began with a residency in Internal Medicine at Hospital Egas Moniz, where he built the foundation for his future work in oncology.
Miguel earned his Master’s in Medicine from the Faculdade de Medicina da Universidade de Lisboa in 2019, which included a year abroad at the Universidad de Salamanca as part of the Erasmus Programme. Early in his career, he developed an interest in oncology research, working at the Instituto de Medicina Molecular in Lisbon. There, he contributed to studies on triple-negative breast cancer (TNBC), focusing on the impact of LDL-c molecules on cancer cell migration, using techniques like immunofluorescence and confocal microscopy.
Miguel has made significant contributions to oncology research, co-authoring several scientific publications, including studies on mitochondrial metabolism and cancer cell migration. He has also presented his findings at national oncology conferences, with topics ranging from rare cancer syndromes to metabolic drivers of cancer progression.
Beyond his research, Miguel is involved in ongoing clinical trials, including the Phase III Olympia trial, which evaluates olaparib's efficacy in patients with BRCA1/2 mutations and HER2-negative breast cancer, and the BRIGHTLINE-1 study on advanced liposarcoma treatments.
He actively pursues professional development through specialized oncology and cardio-oncology courses. Miguel is a member of the European Society of Medical Oncology and the European School of Medical Oncology, staying current with advancements in his field. Fluent in Portuguese, English, and Spanish, Miguel combines clinical expertise with research, contributing to the future of cancer care.
